NCT05623410

Study to Compare the Efficacy and Safety of ATGC-110 (Botulinum Toxin) With Xeomin® for the Treatment of Moderate to Severe Glabellar Frown Lines

A Randomized, Double-Blind, Active-Control, Multicenter, Phase 3 Study to Evaluate the Efficacy and Safety of "ATGC-110" Compared to "Xeomin®" in Patients Who Need Moderate or Severe Glabellar Line Improvement

• Status: Unknown
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 300 (actual)
• Sponsor: ATGC Co., Ltd. · Industry
• Sex: All
• Age: 19 Years – 65 Years
• Healthy volunteers: Accepted

Summary

Efficacy and safety of the investigational product, ATGC-110, was evaluated in comparison with Xeomin for a total of 16 weeks after the administration in treatment of glabellar frown lines.

Conditions

• Glabellar Frown Lines

Interventions

Type	Name	Description
BIOLOGICAL	ATGC-110	ATGC-110 is a prescription medicine that is injected into muscles and used to improve the moderate to severe glabellar lines. It should be reconstituted with sterile, preservative-free 0.9% saline before use.
BIOLOGICAL	Xeomin®	Xeomin® is a prescription medicine that is injected into muscles and used to improve the moderate to severe glabellar lines. It should be reconstituted with sterile, preservative-free 0.9% saline before use.

Timeline

• Start date: 2022-10-11
• Primary completion: 2023-02-10
• Completion: 2023-06-10
• First posted: 2022-11-21
• Last updated: 2023-02-03

Locations

1 site across 1 country: South Korea